DDInter1570 DDInter1376
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ranolazine {u} (Compound) resembles {v} (Compound) Guaifenesin
Ranolazine {u} (Compound) resembles {v} (Compound) Bupivacaine
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
Ranolazine {u} (Compound) upregulates {v} (Gene) DENND2D
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Ranolazine {u} (Compound) downregulates {v} (Gene) ATP6V1D
Ranolazine {u} (Compound) causes {v} (Side Effect) Underweight
Ranolazine (Compound) resembles Guaifenesin (Compound)
Ranolazine (Compound) resembles Bupivacaine (Compound)
Ranolazine (Compound) binds CYP2D6 (Gene)
Ranolazine (Compound) upregulates DENND2D (Gene)
Ranolazine (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Ranolazine (Compound) downregulates ATP6V1D (Gene)
Ranolazine (Compound) causes Underweight (Side Effect)